100 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding risk ... #Diagnosis #Hematology ... CHADS2VASc #HASBLED #Comparison ... #Score #Risk #Stroke
Cholestatic Liver Disease: Primary Biliary Cirrhosis vs Primary Sclerosing Cholangitis

#pathophysiology #pbc #psc #hepatology #comparison
Cholangitis #pathophysiology ... #pbc #psc #hepatology ... #comparison
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... • No bleeding risk ... validated for VTE treatment ... high bleeding risk ... Anticoagulation #Factors #Hematology
Primary Biliary Cirrhosis - Pathophysiology
Environmental Risk Factors: Geographic location, Smoking, Microbial triggers, Xenobiotics, Nail polish
Epigentics Risk
Biliary Cirrhosis - Pathophysiology ... Environmental Risk ... polish Epigentics Risk ... methylation Genetic Risk ... #hepatology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
transfused patientsl • Risk ... : 33% • Treatment ... transfused patients • Risk ... Transfusion #Reactions #hematology ... #diagnosis #comparison
Irritable Bowel Syndrome (IBS) in Pregnancy
 - Pathophysiology
 - Pharmacotherapy
 - Nonpharmacological Treatment

Emory Gastroenterology and Hepatology
in Pregnancy - Pathophysiology ... Nonpharmacological Treatment ... Gastroenterology and Hepatology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
diagnosis and risk-stratification ... • Risks: infection ... only curative treatment ... Diagnosis #Management #treatment ... #hematology #oncology
Suggested algorithm for follow-up of monoclonal gammopathy of undetermined significance (MGUS)
Mayo Clinic Risk Stratification Model. CBC,
) Mayo Clinic Risk ... diagnosis #management #hematology
Pulmonary Embolism Treatment
Systemic Thrombolysis
 - Exclude contraindications.
 - Indications:
   - Massive PE (definite indication)
submassive PE (risk ... 50mg IV) - 2% risk ... of ICH and 6% risk ... who are higher risk ... AcutePE #Management #CriticalCare
NAFLD / NASH Progression Timeline
Healthy Liver → NAFLD/NASH → 0.25-3.2%/year → Cirrhotic NASH → 0.3-2.6%/year →
Cirrhotic NASH Risk ... Cirrhotic NASH → HCC Risk ... Progression #Timeline #hepatology